143 related articles for article (PubMed ID: 26354928)
1. Nevospheres from neurocutaneous melanocytosis cells show reduced viability when treated with specific inhibitors of NRAS signaling pathway.
Basu D; Salgado CM; Bauer BS; Johnson D; Rundell V; Nikiforova M; Khakoo Y; Gunwaldt LJ; Panigrahy A; Reyes-Múgica M
Neuro Oncol; 2016 Apr; 18(4):528-37. PubMed ID: 26354928
[TBL] [Abstract][Full Text] [Related]
2. BRAF mutations are also associated with neurocutaneous melanocytosis and large/giant congenital melanocytic nevi.
Salgado CM; Basu D; Nikiforova M; Bauer BS; Johnson D; Rundell V; Grunwaldt LJ; Reyes-Múgica M
Pediatr Dev Pathol; 2015; 18(1):1-9. PubMed ID: 25490715
[TBL] [Abstract][Full Text] [Related]
3. Amplification of mutated NRAS leading to congenital melanoma in neurocutaneous melanocytosis.
Salgado CM; Basu D; Nikiforova M; Hamilton RL; Gehris R; Jakacki R; Panigrahy A; Yatsenko S; Reyes-Múgica M
Melanoma Res; 2015 Oct; 25(5):453-60. PubMed ID: 26266759
[TBL] [Abstract][Full Text] [Related]
4. Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy.
Ruan Y; Kovalchuk A; Jayanthan A; Lun X; Nagashima Y; Kovalchuk O; Wright JR; Pinto A; Kirton A; Anderson R; Narendran A
Neuro Oncol; 2015 Jun; 17(6):822-31. PubMed ID: 25395461
[TBL] [Abstract][Full Text] [Related]
5. Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor.
Küsters-Vandevelde HV; Willemsen AE; Groenen PJ; Küsters B; Lammens M; Wesseling P; Djafarihamedani M; Rijntjes J; Delye H; Willemsen MA; van Herpen CM; Blokx WA
Acta Neuropathol Commun; 2014 Apr; 2():41. PubMed ID: 24713450
[TBL] [Abstract][Full Text] [Related]
6. The Dual PI3K/mToR Inhibitor Omipalisib/GSK2126458 Inhibits Clonogenic Growth in Oncogenically-transformed Cells from Neurocutaneous Melanocytosis.
Basu D; Salgado CM; Bauer B; Khakoo Y; Patel JR; Hoehl RM; Bertolini DM; Zabec J; Brzozowski MR; Reyes-Múgica M
Cancer Genomics Proteomics; 2018; 15(4):239-248. PubMed ID: 29976629
[TBL] [Abstract][Full Text] [Related]
7. Neurocutaneous Melanocytosis and Leptomeningeal Melanoma.
Mitre V; Heym K; Clark GD; Venkatramani R
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e195-e197. PubMed ID: 31764519
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of NRAS Signaling in Melanoma through Direct Depalmitoylation Using Amphiphilic Nucleophiles.
Vora HD; Johnson M; Brea RJ; Rudd AK; Devaraj NK
ACS Chem Biol; 2020 Aug; 15(8):2079-2086. PubMed ID: 32568509
[TBL] [Abstract][Full Text] [Related]
9. Isothiouronium salts reduce NRAS expression, induce apoptosis and decrease invasion of melanoma cells.
Cisilotto J; Ferreira M; Filippin-Monteiro FB; Bortoluzzi AJ; Sa MM; Creczynski-Pasa TB
Anticancer Agents Med Chem; 2015; 15(3):353-62. PubMed ID: 25469513
[TBL] [Abstract][Full Text] [Related]
10. Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells.
Vujic I; Sanlorenzo M; Esteve-Puig R; Vujic M; Kwong A; Tsumura A; Murphy R; Moy A; Posch C; Monshi B; Rappersberger K; Ortiz-Urda S
Oncotarget; 2016 Feb; 7(6):7297-306. PubMed ID: 26771141
[TBL] [Abstract][Full Text] [Related]
11. Local Inhibition of MEK/Akt Prevents Cellular Growth in Human Congenital Melanocytic Nevi.
Rouillé T; Aractingi S; Kadlub N; Fraitag S; How-Kit A; Daunay A; Hivelin M; Moguelet P; Picard A; Fontaine RH; Guégan S
J Invest Dermatol; 2019 Sep; 139(9):2004-2015.e13. PubMed ID: 31059696
[TBL] [Abstract][Full Text] [Related]
12. MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children.
Kinsler VA; O'Hare P; Jacques T; Hargrave D; Slater O
Br J Cancer; 2017 Apr; 116(8):990-993. PubMed ID: 28253523
[TBL] [Abstract][Full Text] [Related]
13. MUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line.
Rinner B; Gandolfi G; Meditz K; Frisch MT; Wagner K; Ciarrocchi A; Torricelli F; Koivuniemi R; Niklander J; Liegl-Atzwanger B; Lohberger B; Heitzer E; Ghaffari-Tabrizi-Wizsy N; Zweytick D; Zalaudek I
Sci Rep; 2017 May; 7(1):2098. PubMed ID: 28522871
[TBL] [Abstract][Full Text] [Related]
14. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
Atefi M; Titz B; Avramis E; Ng C; Wong DJ; Lassen A; Cerniglia M; Escuin-Ordinas H; Foulad D; Comin-Anduix B; Graeber TG; Ribas A
Mol Cancer; 2015 Feb; 14(1):27. PubMed ID: 25645078
[TBL] [Abstract][Full Text] [Related]
15. Large or multiple congenital melanocytic nevi: occurrence of neurocutaneous melanocytosis in 1008 persons.
Bett BJ
J Am Acad Dermatol; 2006 May; 54(5):767-77. PubMed ID: 16635656
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
17. NRAS
Girolami I; Cima L; Ghimenton C; Zannoni M; Mombello A; Riva G; Cirielli V; Corradi G; Vogrig A; Di Stefano G; Novelli L; Gessi M; Eccher A
Brain Tumor Pathol; 2018 Oct; 35(4):217-223. PubMed ID: 30145692
[TBL] [Abstract][Full Text] [Related]
18. Malignant melanoma arising from an NRAS-mutated medium-sized congenital melanocytic nevus.
Kiyohara T; Takata M; Itoh H; Kawami K; Ido H; Ishida H; Kumakiri M
J Dermatol; 2012 Dec; 39(12):1034-5. PubMed ID: 22452623
[No Abstract] [Full Text] [Related]
19. Severe hydrocephalus caused by diffuse leptomeningeal and neurocutaneous melanocytosis of antenatal onset: a clinical, pathologic, and molecular study of 2 cases.
Uguen A; Laurent C; Samaison L; Boisselier B; Talagas M; Costa S; Aziza J; Mokhtari K; Le Maréchal C; Marcorelles P
Hum Pathol; 2015 Aug; 46(8):1189-96. PubMed ID: 26037215
[TBL] [Abstract][Full Text] [Related]
20. Genetic Abnormalities in Large to Giant Congenital Nevi: Beyond NRAS Mutations.
Martins da Silva V; Martinez-Barrios E; Tell-Martí G; Dabad M; Carrera C; Aguilera P; Brualla D; Esteve-Codina A; Vicente A; Puig S; Puig-Butillé JA; Malvehy J
J Invest Dermatol; 2019 Apr; 139(4):900-908. PubMed ID: 30359577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
